All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2005-003382-16 | Pilot randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial). | 2008-03-04 | due-trials |
| Completed, but no date Terminated | 2005-004569-40 | Phase I and II perspective study with Citrate in Liposoma not Pegilate Doxorubicine TLC D-99 in association to Ifosfamide in patients with metastatic soft tissue sarcoma. | bad-data | |
| Completed, but no date | 2006-001409-27 | Pegfilgrastim versus filgrastim after high-dose chemotherapy followed by autologous peripheral blood stem cell, in patients with hematologic and solid tumors a randomized phase II study | bad-data | |
| Completed, but no date | 2006-004429-27 | Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma | bad-data | |
| Completed, but no date | 2006-004437-15 | FASE II PROSPECTIVE STUDY BAY-43-90006 IN ADVANCED, METASTATIC SOFT TISSUE SARCOMAS, AFTER ANTRACYCLINE-BASED THERAPY FASE II PROSPECTIVE STUDY BAY-43-90006 IN ADVANCED, METASTATIC SOFT TISSUE SARC... | bad-data | |
| Completed, but no date Terminated | 2007-000758-30 | Randomized continuation, dose escalation trial of Sorafenib in pts with advanced HCC with radiological progression on prior sorafenib treatment (Phase II study) | bad-data | |
| Completed, but no date Terminated | 2007-003709-29 | Prospective phase II trial evaluating efficacy of Trastuzumab therapy in HER2 FISH positive and/or HER2 mutation positive, pretreated, Non-Small Cell Lung Cancer patients (MO20509) | bad-data | |
| Completed, but no date | 2007-004883-29 | IGEV +/- Bortezomib (VelcadeTM) as induction before high dose consolidation in relapsed/ refractory Hodgkins lymphoma after first line treatment : a randomized phase II trial | bad-data | |
| Ongoing | 2008-002126-12 | A randomized phase II study of progression free survival comparing gemcitabine (1250 mg/m2 infusion) versus carboplatin (AUC5 infusion) plus alimta (500 mg/m2 infusion) as first-line chemotherapy in e... | not-yet-due | |
| Ongoing | 2008-003202-33 | Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome | not-yet-due | |
| Completed, but no date | 2008-005714-46 | BIOLOGICALS SUPPORTS STUDY IN RESECTIVE SURGERY OF PANCREATIC | bad-data | |
| Completed, but no date | 2009-010672-16 | PHASE II STUDY OF SUNITINIB IN METASTATIC RENAL CANCER WITH NON-CLEAR CELL HISTOLOGY | bad-data | |
| Completed, but no date | 2009-011763-37 | THE ANTI-ANGIOGENIC EFFECTS OF ADALIMUMAB IN CROHN`S DISEASE | bad-data | |
| Completed, but no date, and reported results | 2010-019683-37 | PHASE II STUDY OF EVEROLIMUS IN PATIENTS WITH THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY | bad-data | |
| Completed, but no date | 2010-022169-91 | PHASE II STUDY WITH BENDAMUSTINE GEMCITABINE AND VINORELBINE (BeGEV) AS INDUCTION THERAPY IN RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA PATIENTS BEFORE HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC... | bad-data | |
| Not reported Terminated | 2010-023411-33 | A phase II, randomized, double-blind, placebo controlled trial of Sorafenib as adjuvant treatment for hepatocellular carcinoma after TACE-based treatments. Studio di Fase II, randomizzato, in doppi... | 2013-05-07 | due-trials |
| Ongoing | 2011-002122-43 | Iron therapy in IBD patients with normal levels of haemoglobin and chronic fatigue Effetti della terapia marziale in pazienti con fatica cronica e IBD | not-yet-due | |
| Ongoing | 2011-003080-30 | WEIGHT-ADJUSTED LOW MOLECOLAR WEIGHT HEPARIN IN RECURRENT IMPLANTATION FAILURE: A RANDOMIZED OPEN LABELED TRIAL Eparina a basso Peso Molecolare a dosaggio aggiustato per il peso corporeo in fallime... | not-yet-due | |
| Ongoing | 2012-003213-34 | MEthylprednisoloneNacinHepatIcResections “MENHIR” MEthylprednisoloneNacinHepatIcResections 'MENHIR' | not-yet-due | |
| Ongoing | 2012-005337-37 | ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE Ruolo dell’Ormone Antimülleriano (AMH) quale marcatore della riser... | not-yet-due | |
| Completed, but no date Terminated | 2012-005338-13 | OFATUMUMAB-BENDAMUSTINE FOR RELAPSED/REFRACTORY INDOLENT LYMPHOMA: A MULTICENTER PHASE 2 TRIAL OFATUMUMAB–BENDAMUSTINA PER I LINFOMI INDOLENTI RECIDIVANTI/REFRATTARI: UNO STUDIO MULTICENTRICO DI FA... | bad-data | |
| Not reported | 2012-005578-79 | A single-Arm Phase II Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS Studio di ... | 2016-11-04 | due-trials |
| Completed, but no date | 2012-005580-27 | MULTI-CENTER, PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING REDUCED INTENSITY CONDITIONING (RIC) REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE, IN... | bad-data | |
| Ongoing | 2014-001093-34 | An Open-Label Phase II Study of regorafenib In Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Studio di fase II in aperto sull’uso di regorafenib in pazi... | not-yet-due | |
| Completed, but no date | 2014-002579-27 | Pilot study on the efficacy of golimumab in the induction and maintenance of clinical and endoscopic remission in patients with steroid-dependent ulcerative colitis. | bad-data | |
| Ongoing | 2014-002876-10 | A PHASE II STUDY OF THE COMBINATION OF GEMCITABINE AND IMATINIB MESYLATE IN PEMETREXED-PRETREATED PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA STUDIO DI FASE II DELLA COMBINAZIONE DI GEMCITABINA... | not-yet-due | |
| Completed, but no date Terminated | 2015-004543-40 | A SINGLE ARM, PHASE II, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF VISMODEGIB AND RADIOTHERAPY IN PATIENTS WITH HIGH RISK OR LOCALLY ADVANCED BASAL CELL CARCINOMA NOT AMENABLE TO RADICAL S... | bad-data | |
| Completed, but no date Terminated | 2015-004713-24 | A Multicenter, Open Label, Pilot Study to Investigate Tolerability and Efficacy of MK5172 (Grazoprevir) / MK8742 (Elbasvir) Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection Wi... | bad-data | |
| Completed, but no date | 2016-002707-25 | Comparison between two therapeutic strategies for the maintenance of clinical and endoscopic remission in patients with ulcerative colitis treated by infliximab (SCILLA). Confronto tra due strategi... | bad-data | |
| Ongoing | 2016-004004-60 | Prospective study of anti-inflammatory therapy post interventional radiological treatment of HCC in the cirrhotic patient. Studio prospettico della terapia anti-infiammatoria dopo trattamenti di Ra... | not-yet-due | |
| Exempt | 2016-004118-84 | A multicenter, phase I-II trial of gemcitabine plus oxaliplatin and nbb-paclitaxel in subjects with advanced (unresectable or metastatic) biliary tract cancer (gallbladder cancer, cancer of the extrah... | not-yet-due | |
| Completed, but no date | 2016-004510-99 | PERFORMANCE OF BIORESORBABLE POLYMER-COATED EVEROLIMUS-ELUTING SYNERGY® STENT IN PATIENTS AT HIGH BLEEDING RISK UNDERGOING PERCUTANEOUS CORONARY REVASCULARIZATION FOLLOWED BY 1-MONTH DUAL ANTIPLATELET... | bad-data | |
| Ongoing | 2017-002012-13 | EXPLORATIVE STUDY ON THE BIOLOGICAL MECHANISMS INVOLVED IN THE PATHOGENESIS OF PSORIASIS STUDIO ESPLORATIVO SUI MECCANISMI BIOLOGICI COINVOLTI NELLA PATOGENESI DELLA PSORIASI | not-yet-due | |
| Not reported | 2017-004618-24 | Evaluation of CardioprOtection by the use of betablocker Nebivolol in paTients with bReast cancer Or diffuse Large B cell lymphoma undergoing chemotherapy with anthracyclines: a randomized controlled ... | 2023-02-24 | due-trials |
| Not reported | 2017-005034-36 | An Italian database-based randomized controlled trial with Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Studio randomizzato controllato con rituximab ... | 2023-07-30 | due-trials |
| Ongoing | 2018-000495-15 | n.a. Studio multicentrico, randomizzato, a gruppi paralleli di fase IV, per confrontare efficacia, sicurezza e tollerabilità di PLENVU® (preparazione per pulizia intestinale 1 L a base PEG+ASC) ris... | not-yet-due | |
| Ongoing | 2018-000680-93 | Postoperative effects of high-dose esmolol during mitral valve surgery for mitral regurgitation. ESMOLOLO IN CHIRURGIA MITRALICA | not-yet-due | |
| Not reported | 2018-001347-31 | Anti-nerve reactivity as predictor of response to immune therapy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A proof of concept study with rituximab in patients... | 2023-03-22 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-002722-22 | Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS) | 2023-08-24 | bad-data |
| Ongoing | 2019-002451-42 | nd Valutazione dell’outcome clinico tra la terapia sub-linguale PCA con sufentanil e la terapia per os associata a single shot peri-femorale nel percorso Fast Track della chirurgia protesica tota... | not-yet-due | |
| Other | 2019-002860-29 | Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A Phase II study (Immunocabo). Studi... | not-yet-due | |
| Completed, report not yet due | 2019-004250-28 | EXPLORING THE EFFECTS OF IL-23 INHIBITION BY RISANKIZUMAB ON PSORIASIS AUTOIMMUNITY. ESPLORARE GLI EFFETTI DELL'INIBIZIONE IL-23 DI RISANKIZUMAB SULL'AUTOMUNITÀ DELLA PSORIASI. | 2024-07-18 | not-yet-due |
| Ongoing | 2020-003119-88 | EVALUATION OF AUTOIMMUNITY IN PSORIASIS FOLLOWING IL-17A NEUTRALIZATION: A BASE TO OPTIMISE USE OF BIOLOGICS IN PSORIASIS Valutazione dell’autoimmunità nella psoriasi dopo inibizione di IL-17A al f... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2020-003420-16 | SPRINT: AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE STEP-UP VS TOP-DOWN TREATMENT ALGORITHMS IN MODERATE TO SEVERE ULCERATIVE COLITIS | 2022-04-28 | bad-data |
| Other | 2020-005902-24 | Phase II Clinical Trial to optimize the dose of an anti-NKG2A monoclonal antibody (humZ270 mAb, IPH2201) for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing haploidentical ... | not-yet-due | |
| Ongoing | 2021-003751-42 | Randomized phase III clinical trial of Neo-Adjuvant Intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve vesical neoplasms. Studio clinico randomizzato di fase III sull... | not-yet-due | |
| Other | 2022-001147-24 | Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatment -... | not-yet-due |